Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Dipeptidyl Peptidase IV (DPP-IV) is a proteolytic enzyme that specifically cleaves dipeptides from the N-terminus of proteins and peptides. This enzyme targets proline-containing peptides found in gluten and casein, potentially reducing digestive discomfort in sensitive individuals.
Reported Benefits (Provisional)
Origin & History
Dipeptidyl Peptidase IV (DPP-IV) is an enzyme found in the intestines, known for its role in breaking down dietary proteins, particularly gluten and casein. It is naturally produced in the body and can be supplemented for digestive support.
Research Narrative (Provisional)
Research includes clinical trials and in vitro studies examining its role in protein digestion and potential benefits for gluten sensitivity.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Involved in the breakdown of proline-rich peptides. - Naturally occurring in the digestive tract. - Activity can be influenced by dietary factors.
Reported Mechanism (Provisional)
DPP-IV cleaves dipeptides containing proline and hydroxyproline residues from the N-terminus of peptide chains through its serine protease activity. The enzyme specifically targets immunogenic peptides like α-gliadin fragments from gluten and β-casomorphins from casein, breaking them into smaller, less reactive compounds. This proteolytic action occurs in the small intestine, reducing the antigenic potential of these proteins before immune recognition.
Clinical Narrative (Provisional)
Clinical evidence for DPP-IV supplementation remains limited, with most studies conducted in vitro or using animal models. A small human pilot study (n=20) showed modest reduction in gluten-related symptoms when DPP-IV was taken with gluten-containing meals. However, larger randomized controlled trials are lacking, and current evidence does not support DPP-IV as a treatment for celiac disease. Most research focuses on symptom management in non-celiac gluten sensitivity rather than complete protein breakdown.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.